Significant biosimilar activities this week include:
 

  • June 28 US: Genentech filed a complaint against Samsung Bioepis in the District Court of Delaware under the BPCIA, alleging infringement of 14 patents related to SB8 (Samsung's proposed bevacizumab biosimil...

Significant biosimilar activities this week include:

  • June 14: Celltrion presented new data from Phase II trials of a Truxima® (biosimilar rituximab), lenalidomide and acalabrutinib regime for the treatment of relapsed/refractory aggressive B-cell lymphoma.  Celltrio...

Please reload

Biosimilars bulletin 

October 4, 2020

Please reload

Search by tags